RANCHO CORDOVA, Calif.,
April 2, 2020 /PRNewswire/ --
ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in
automated cell processing tools and services in the cell and gene
therapy field, announced today that it was featured on a FOX40 news
segment titled, "Rancho Cordova Company Develops Antibody Test to
Detect COVID-19 in Minutes," regarding the Company's SARS-CoV-2
(COVID-19) IgM/IgG Antibody Fast Detection Kit. Requiring just a
single drop of blood, the Kit is intended for professional use
and will deliver results -- with no lab equipment necessary -- in
less than 10 minutes, at the point-of-care. The Kit is designed
to allow pre-screening for COVID-19 infections as well as
identification of individuals who have encountered the virus and
have developed protective immunity.
As announced on March 31,
ThermoGenesis is currently conducting validations of the SARS-CoV-2
(COVID-19) IgM/IgG Antibody Fast Detection Kit in accordance
with the U.S. Food and Drug Administration (FDA) regulation,
"Policy for Diagnostic Test for Coronavirus Disease – 2019 during
the Public Health Emergency: Immediately in Effect Guidance for
Clinical Laboratories, Commercial Manufacturers, and Food and Drug
Administration Staff issued on March 16,
2020 for Serological Diagnostics." The Company will
notify the FDA upon completion of validation, prior to product
launch.
The FOX40 News is accessible via the link below:
-
https://fox40.com/news/local-news/rancho-cordova-company-develops-blood-test-to-detect-covid-19-in-minutes/
The Company has also updated its website to include information
on the SARS-CoV-2 (COVID-19) IgM/IgG Antibody Fast Detection Kit.
The website update is for educational purposes and will allow users
to better understand how the antibody test works and how to
evaluate the results. Please visit the link below:
-
https://thermogenesis.com/rapid-covid-19-point-of-care-diagnostic-test/
"From the point that you have your blood dropped, three minutes
later you know the results," Philip Coelho, chief technology
officer at ThermoGenesis Corp., told FOX40. Mr. Coelho also noted
that the FDA is fast-tracking products related to the virus "So,
they're particularly interested in encouraging the types of
technologies that will help assist a safe transition back to a
working state of the country," Coelho said.
Inquiries from health professionals and the media about the Kit
should be directed via email to ir@thermogenesis.com.
About ThermoGenesis Holdings, Inc.
ThermoGenesis Holdings, Inc. develops, commercializes and
markets a range of automated technologies for CAR-T and other
cell-based therapies. The Company currently markets a full suite of
solutions for automated clinical biobanking, point-of-care
applications, and automation for immuno-oncology, including its
semi-automated, functionally-closed CAR-TXpress™ platform,
which streamlines the manufacturing process for the emerging CAR-T
immunotherapy market. For more information about ThermoGenesis,
please visit: www.thermogenesis.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Forward-looking statements are not statements of historical
facts, but rather reflect the current expectations of ThermoGenesis
concerning future events and results. Forward-looking statements
based on ThermoGenesis' current assumptions, expectations and
beliefs are generally identifiable by use of words "may," "might,"
"will," "should," "expects," "plans," "anticipates," "believes,"
"estimates," "predicts," "potential" or "continue," or similar
expressions and involve significant risks and uncertainties that
could cause actual results, developments and business decisions to
differ materially from those contemplated by these statements. Such
forward-looking statements, including statements regarding the
intended use of net proceeds from the registered direct offering as
well as those factors concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, market
and other conditions, as well as those risk factors discussed in
Item 1A of our most recent Annual Report on Form 10-K filed with
the Securities and Exchange Commission ("SEC") as well as other
documents that may be filed by ThermoGenesis from time to time with
the SEC, which are available at www.sec.gov. We undertake no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as required by law. You are cautioned not to
unduly rely on such forward-looking statements when evaluating the
information presented in this press release.
Company Contact:
Wendy
Samford
916-858-5191
ir@thermogenesis.com
Investor Contact:
Paula Schwartz, Rx
Communications
917-322-2216
pschwartz@rxir.com
View original
content:http://www.prnewswire.com/news-releases/thermogenesis-rapid-covid-19-serological-test-kit-featured-on-fox40-news-story-titled-rancho-cordova-company-develops-antibody-test-to-detect-covid-19-in-minutes-301034196.html
SOURCE ThermoGenesis Holdings, Inc.